RealTime Software Solutions

RealTime Software Solutions

RealTime Software Solutions builds and maintains a suite of electronic clinical outcome assessment and clinical trial management tools purpose-built for the operational complexity of modern drug development. The San Antonio-based company focuses on the intersection of clinical operations, site management, and patient engagement, serving CROs and biopharma sponsors who run studies across oncology, rare disease, and central nervous system indications. The platform is designed to handle the real-time data collection and monitoring requirements mandated by trial protocols, including direct data capture from patients and remote monitoring dashboards for clinical research associates. The firm's technology stack addresses the logistics of trial execution—patient scheduling, electronic informed consent, site payments, and visit tracking. Deployment occurs across North America and Europe. The product line includes RTMS for site-based management, and eCOA tools for patient-reported outcomes. This dual architecture separates the administrative governance of a trial site from the longitudinal collection of patient data, aligning the software footprint with typical trial sponsor-vendor governance models. No significant fund commitments or large institutional capital raises are publicly documented, consistent with a bootstrapped or organically-funded operational model. The company maintains a concentrated footprint in San Antonio with no known additional offices, operating in a market sector where specialist service providers frequently become acquisition targets for larger clinical data platforms. Recent public records indicate standard business continuity with ongoing support for clinical trials and software updates. The precise team size is not public, but the nature of the software and the regulatory environment suggests a focused group of developers and domain experts. RealTime Software Solutions operates in a sector with high barriers to validation—any system capturing clinical trial data must meet FDA 21 CFR Part 11 compliance. This regulatory barrier acts as a structural moat, because replacing a validated electronic data capture system mid-trial is operationally prohibitive for sponsors. The firm's structural differentiator lies in the lock-in created when a trial's entire data pipeline is built on its software, which then creates a recurring relationship across phases and sites for a given sponsor.